SCHEMBL1721202

SCHEMBL1721202

CCSc1nc2cc(C(F)(F)F)ccc2c(C)c1C(=O)NCc1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.43
TACR1 P25103 3/20 0.41
MAOB P27338 2/20 0.41
SORT1 Q99523 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
PTGER4 P35408 1/20 0.38
PTGES O14684 1/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LSS P48449 1/20 0.38
PPARA Q07869 2/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
EPHX2 P34913 2/20 0.37
PPARG P37231 2/20 0.37
PSMD14 O00487 1/20 0.37
STAMBP O95630 1/20 0.37
CHRM4 P08173 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721222 0.95 SORT1 (0.43) TACR1SORT1PTGER4PTGESKDM4E
SCHEMBL1721672 0.93 LMNA (0.42) TACR1MAOBSORT1PTGER4PTGES
SCHEMBL1721504 0.93 EPHX2 (0.43) TACR1SORT1EPHX2
SCHEMBL1722444 0.93 SMN1; SMN2 (0.43) TACR1SORT1PTGER4KDM4EL3MBTL1
SCHEMBL1722120 0.92 CNR1 (0.46) TACR1PTGER4PTGESCNR1CNR2
SCHEMBL1722065 0.91 TACR1 (0.48) TACR1SORT1PTGER4KDM4EL3MBTL1
SCHEMBL1721136 0.91 SORT1 (0.49) TACR1SORT1PTGER4KDM4E
SCHEMBL1722789 0.90 ALDH1A1 (0.48) PTGER4KDM4EL3MBTL1EPHX2CHRM4
SCHEMBL1721577 0.90 EPHX2 (0.48) TACR1SORT1PTGER4PTGESKDM4E
SCHEMBL1721320 0.90 MLYCD (0.41) TACR1MAOBTRPV1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399673-B2 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-03-19 US claimed
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators DRUNENTHAL GMBH (DE) 2012-10-04 US claimed
EP-2406229-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-01-18 EP claimed
WO-2010102811-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2010-09-16 WO claimed
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2010-09-16 US claimed
US-8399673-B2 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-03-19 US disclosed
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators DRUNENTHAL GMBH (DE) 2012-10-04 US disclosed
EP-2406229-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-01-18 EP disclosed
WO-2010102811-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2010-09-16 WO disclosed
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS GRUNENTHAL GMBH (DE) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234372-A1 SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS KCNQ1, KCNQ2, KCNJ2 MTOR 3301/4885TACR1 2800/4885MAOB 2310/4885
US-20120252841-A1 Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators KCNQ1, KCNQ2, KCNJ2 MTOR 3301/4885TACR1 2800/4885MAOB 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.